Overview

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

Status:
Active, not recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Phase:
Phase 2
Details
Lead Sponsor:
Restorbio Inc.
Collaborator:
National Institute on Aging (NIA)
Treatments:
Dactolisib